RecruitingNCT05766384

Hyperpolarized 129Xe MRI Lung Health Cohort

Hyperpolarized 129Xe MRI to Identify Structural Determinants of Low Lung Function and Respiratory Symptoms in Young Adults From the Lung Health Cohort


Sponsor

University of Kansas Medical Center

Enrollment

260 participants

Start Date

Nov 30, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.


Eligibility

Min Age: 25 YearsMax Age: 35 Years

Inclusion Criteria2

  • Is enrolled in the American Lung Association Lung Health Cohort Study.
  • Has completed CT imaging for the LHC study within 2 years of the scheduled Xe-MRI date.

Exclusion Criteria3

  • Pacemaker, internal defibrillator or other implanted electronic devices or any standard MRI contraindications (e.g., claustrophobia, > 140 cm shoulder circumference, dependent on weight distribution).
  • Is pregnant or breastfeeding
  • Oxygen saturation (SpO2) <88% on room air or with supplemental oxygen.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHyperpolarized Xe129

Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.


Locations(6)

University of Illinois-Chicago

Chicago, Illinois, United States

University of Iowa

Iowa City, Iowa, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

Duke University

Durham, North Carolina, United States

Baylor College of Medicine

Houston, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05766384


Related Trials